AMS-17 is a potent NLRP3 inhibitor, which effectively suppresses microglia activation both in vitro and in vivo. Additionally, AMS-17 exhibits inhibitory effects on various cytokines, such as caspase-1, TNF-α, IL-1β, and inducible nitric oxide synthase (iNOS), in N9 cells. Given these properties, AMS-17 holds promise as a valuable tool for investigating inflammation-associated neurological disorders [1].